Nancy J. Hutson - 13 Jun 2023 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: Director
Signature: /s/ Alane P. Barnes, by power of attorney
Issuer symbol: BCRX
Transactions as of: 13 Jun 2023
Net transactions value: -$103,443
Form type: 4
Filing time: 15 Jun 2023, 16:33:37 UTC
Previous filing: 19 May 2023
Next filing: 23 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Award	$0	+16,745	+21%	$0.000000	94,684	13 Jun 2023	Direct	F1
transaction	BCRX	Common Stock	Sale	$103,443	-12,866	-14%	$8.04	81,818	14 Jun 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCRX	Automatic Stock Option Grant	Award	$0	+39,072		$0.000000	39,072	13 Jun 2023	Common Stock	39,072	$8.18	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2	The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $7.89 to $8.12. The reporting person will provide to the issuer, or any security holder of the issuer, or the SEC staff upon request, full information regarding the number of shares purchased at each price within the range set forth in the footnote.
F3	Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.